Zhongke Kangsa Biotechnology (Chongqing) Co., Ltd.

Zhongke Kangsa is the main listed company of Kangsa Biotechnology.
Kangsa Biotechnology Company is a key high-tech biotech enterprise introduced by Liangjiang New Area. (It independently owns Chongqing's current 10,000-grade standard cell preparation center). It has currently invested 100 million RMB. Office area is 10,000 square meters. The company is engaged in basic research related to stem cells-regenerative medicine, stem cells-immunotherapy, and immune cells-tumor therapy, as well as the research and development of new cell biotherapy technologies and new drugs, product clinical translation, and the introduction and service consulting of new technologies in related fields. It is currently applying for the Chongqing Cell Therapy Technology Application Demonstration Center.
Kangsa Biotechnology floor distribution: 1st floor cell storage bank, 2nd floor office center, 3rd floor cell preparation center, 4th floor drug research and development center, 5th floor medical clinic.
I. Project cooperation and introduction of cooperating experts:
1. Meng Songdong (introduced talent under the Chinese Academy of Sciences "Hundred Talents Program"; professor, doctoral supervisor, head of the Cellular Immunology Research Group of the Chinese Academy of Sciences, researcher at the Institute of Microbiology; judge of the National Science and Technology Award, member of the Chinese Academy of Sciences Biomedical Project Review Expert Database; authorized 10 national invention patents.)
2. Li Lei (postdoctoral fellow at the University of Toronto, Canada; former director of the *** research office of the State Key Laboratory of Trauma, Burns and Combined Injury of the former Army Medical University)
3. Professor Yu Jian (tenured professor in the Department of Pathology and Physiology at the University of Pittsburgh, USA; received a doctorate from Johns Hopkins University, USA; has long been engaged in intestinal stem cell research; has obtained 5 US NIH projects; has published more than 100 papers in national *** publications such as Science and Nature; world *** expert in the field of stem cell research)
4. Long Jiaoyue (Ph.D.)
Postdoctoral fellow at Albany Medical College, USA. Has published 9 articles in international journals and participated in international academic conferences many times. Presided over and participated in 4 National Natural Science Foundation projects and multiple innovation funds. Mainly studies the effects of cells and molecules on gene expression and the molecular mechanisms of connexin 43-mediated mesenchymal stem cell protection against high glucose-induced endothelial cell injury, etc.
5. Professor Cui Hongjuan (professor at Southwest University ***)
Director of the Chongqing Biomaterials and Regenerative Medicine Engineering Research Center, selected participant of Chongqing's "Hundred Overseas High-level Talent Gathering Program", high-level innovative talent introduced by Southwest University under the "Hundred Talents Program", engaged in scientific research and talent cultivation in the field of cell biology-stem cell biology.
...etc.
II. University co-construction: jointly build with Chongqing University and the Industrial Research Institute: "Chongqing Cell Quality Research and Translation Base"
III. Company plans:
Become a Chongqing key laboratory; establish an academician workstation; establish a postdoctoral workstation; NK kit production (replace Japanese NK kits); stem cell gel (drug for treating *** cervical erosion); introduction of stem cell orphan drugs already approved by the US FDA; complete the application and production of its own Phase III clinical cell pharmaceutical drugs; cooperate with units that have obtained Phase III clinical qualifications to jointly produce cell drugs.